{
    "2020-04-22": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Hedge Fundsâ€™ This Stock Pick Debunked Naysayers",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Stock Pick",
                        "Debunked",
                        "Naysayers"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "Johnson & Johnson Lifted to Buy as Outperformer in `Difficult Times'",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Lifted",
                        "Buy",
                        "Outperformer",
                        "Difficult Times"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "These 'Healthy' Stocks Tip The Coronavirus Market In Your Favor",
                "features": {
                    "keywords": [
                        "Healthy Stocks",
                        "Coronavirus",
                        "Market",
                        "Favor"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "AbbVie Gets FDA Nod for Imbruvica+Rituxan in First-Line CLL",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "Imbruvica",
                        "Rituxan",
                        "First-Line",
                        "CLL"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}